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ABSTRACT
Introduction. Preimplantation genetic testing (PGT) is growing in importance and volume 
internationally. International societies such as ESHRE compile international results and these data are 
published in scientific journals. We present the first compilation of practices, quality measures and 
outcome data from Nordic clinics performing PGT. Material and methods. We conducted a 
structured online survey of PGT practices in the Nordic countries to compare clinical and laboratory 
techniques, outcomes and quality measures applied in Nordic clinics. The survey was designed by the 
authors and answered by the authors and members of the study group. The outcome data represents 
results from 2018. Results and details were clarified through iteration with responding clinics while 
maintaining anonymity. Response rate in the study was 80%, with eight of ten clinics performing 
PGT responding. Results. Most of the PGT cycles in the Nordic countries are funded through the 
public health care system with University Hospitals performing the majority of treatments, 716/848 or 
84.4% of oocyte retrievals in this dataset. The genetic analyses are in five cases performed by the 
affiliated local genetic laboratory, while the remaining three consult with large international private 
enterprise laboratories. Genetic counselling is widely used. Results in the Nordic clinics compare well 
with international data. Systematic quality control procedures are in place and the larger clinics and 
laboratories utilize ISO certification or accreditation in the quality management. Automatic 
witnessing with detailed electronic documentation of laboratory processes is not utilized in the 
responding clinics although a majority uses manual witnessing procedures in the laboratory. The 
outcome after PGT in terms of clinical pregnancy per transfer is around 40% per embryo transfer and 
compares well with international data. Conclusions. PGT is organised in rather few clinics in the 
Nordic countries and most of them use local laboratories for genetic analyses of the biopsies. 
Laboratory procedures are largely in accordance with international guidelines and the outcome after 
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Abbreviations
PGT-A preimplantation genetic testing for aneuploidies
PGT-M preimplantation genetic testing for monogenic disorders
PGT-SR preimplantation genetic testing for structural rearrangements
ART assisted reproduction technologies
MPS Massive Parallel Sequencing
IVF in vitro fertilization
ESHRE European Society for Human Reproduction and Embryology
ICSI intracytoplasmic sperm injection
Key Message
Preimplantation genetic testing is performed in only a few of the IVF-clinics in the Nordic countries, 
most of them relying on local laboratories for genetic analyses. Laboratory procedures are largely in 
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INTRODUCTION
Preimplantation genetic testing (PGT) in combination with assisted reproduction technology (ART) 
treatment can be used as an alternative to traditional prenatal diagnosis in cases where there is a high 
risk of a genetically affected fetus due to known familial monogenetic mutations (PGT-M) or 
structural chromosomal rearrangements (PGT-SR). Being performed before implantation and by 
deselection of genetically affected embryos, PGT is a preferred option for couples who want to avoid 
termination of an affected pregnancy. For PGT-SR the procedure additionally elevates the chances of 
achieving a successful pregnancy per embryo transfer as all aneuploid embryos are most often 
deselected in addition to the embryos carrying the already known familial chromosomal aberration in 
an unbalanced form. Preimplantation genetic testing can also be used to establish a pregnancy with an 
embryo which is human leukocyte antigen (HLA) matched to a sibling having a hematological or 
immunological disease in need of a life-saving bone marrow transplantation.1 Yet another PGT 
application is exclusion testing where individuals who may be at-risk for a late onset disease such as 
Huntington’s disease, and who wish to prevent the birth of a carrier child without disclosure of their 
own carrier status may be eligible for PGT. This is achieved by avoiding the transfer of embryos 
carrying a HTT (huntingtin) gene allele from the affected family member, thus preserving the 
individual’s right not to know.2
Finally, PGT can be used to screen embryos for chromosomal aberrations or aneuploidies (PGT-A) 
with the aim to optimize the in vitro fertilization (IVF)-treatment in couples lacking known familial 
genetic disease. Chromosomal aneuploidy is likely to be one of the main reasons why only 30-50% of 
human blastocysts result in a live birth after transfer. Thus, not only the decrease in implantation rate 
by female age, but also the increased risk of miscarriage can be explained by aneuploidy, increasing 
from 25%-30% for patients in their twenties to about 70-90% in patients above 40 years of age.3 
Screening of human embryos by PGT and selection of embryos with normal chromosome numbers is 
therefore expected to have the potential to increase the chance of pregnancy per transfer in ART, to 
reduce the risk of miscarriage and accordingly reduce the time to pregnancy.4 Comprehensive 
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However the true impact on the cumulative pregnancy rate is not yet fully known as some discarded 
aneuploid embryos do have the potential to give rise to healthy babies.6 Routine use of PGT-A in 
infertility treatment is therefore questioned and a subject of intense discussion.7, 8
The first PGT in humans leading to pregnancy was performed in 1990 by blastomere biopsy of 
cleavage stage embryos.9 Since then PGT has moved from an experimental procedure to a specialized 
test which is currently performed on a large scale in many centers worldwide. Today PGT is in most 
cases performed by genetic analysis of biopsied trophectoderm cells from blastocyst stage embryos  
which may require whole genome amplification of the biopsied material before analysis (e.g. 
microarray, karyomapping, massive parallel sequencing (MPS)). This development has been 
supported by significant improvements in cryopreservation methods, now yielding embryo survival 
rates after vitrification exceeding 90% and which have a similar implantation rate as fresh embryos.10 
The genetic analysis can be time consuming and as a consequence requires cryopreservation and 
storage of all tested embryos until results are obtained.
Worldwide data on PGT are collected by the PGT consortium under the European Society for Human 
Reproduction and Embryology (ESHRE). The last report covered data from 71 centers performing 11 
637 cycles resulting in 2 147 pregnancies (De Rycke personal communication).11 PGT-A represented 
52% of the 11 637 cycles reported. PGT-M requires a more thorough genetic work up of the couple, 
demanding highly specialized procedures, which may partly explain why PGT-M represent only 
around 30% of all PGT activity in the European register and 12% in the USA.11, 12 While PGT-M and 
PGT-SR are performed to reduce the risk of a genetically affected child, the motivation to perform 
PGT-A is often related to ART efficacy, both during infertility treatment and as an add-on to PGT-
M/SR.
With increasing utilization of PGT, the need for specialized genetic counselors has increased 
dramatically. In many countries special educational programs exist with the profession of genetic 
counselors being well established. An example of this is the US in which the first formalized training 
programs started in the late 1960’s. In the Nordic countries, only Norway has a formal Masters (MSc) 
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genetic counselor status also in the other Nordic countries. Usually the counselors are clinical 
geneticists, specialized nurses or other trained health care professionals.13
Guidelines for best practice have been published both by ESHRE and The Preimplantation Genetic 
Diagnosis International Society (PGDIS).14-17, 18 New versions of the ESHRE guidelines are in the 
final stages of review and the stakeholder versions have been accessed as background material for this 
study.19-22
Regulations for the use of PGT and the degree of governmental funding vary greatly across countries 
and continents.23
The aim of the present study was to describe the current status of activity, practices, quality, use and 
results for PGT in the Nordic countries.
MATERIAL AND METHODS
The study was performed as an on-line survey (SurveyMonkey) distributed to all Nordic clinics 
performing PGT. This included IVF clinics in Denmark, Finland and Sweden as clinics in Norway 
and Iceland do not currently perform PGT with patients utilizing centres in the neighbouring Nordic 
countries. At least one author acted as a contact person in each country and distributed access to the 
survey via a web link. The survey was open from September 9th to September 27th 2019.
To the authors’ best knowledge, ten IVF clinics were performing PGT in the Nordic countries in 
2018. In 2019 one additional clinic started performing PGT, however the data presented here only 
refer to the year 2018. We received responses from eight of the ten clinics performing PGT in 2018, 
four from Denmark, two from Sweden and two from Finland, giving a total response rate of 80% and 
100% coverage for PGT in Denmark and Sweden. According to the Finnish ART data collection, 53 
PGT-M/SR transfers and 66 PGT-A transfers were reported for 2018. We report data on 47 and 29 of 
these cycles, respectively. The clinics all cooperate with a Clinical Genetics department, where some 
have a strong affiliation with a local University Clinical Genetics department and others send the 
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Each clinic was assigned a number according to the time of response to the online survey, not 
according to country or any alphabetical arrangement.
All results presented are from the year 2018 in order to present the current status in the Nordic 
countries. A clinical pregnancy was defined as an implantation (the presence of a gestational sac) 
confirmed by ultrasound scan and the clinical pregnancy rate as the number of clinical pregnancies 
divided by the number of (frozen) embryo replacements. Ongoing pregnancy was defined as a viable 
pregnancy with confirmed foetal heart beat at >6 weeks of pregnancy. Pregnancy loss was defined as 
the difference between the number of clinical pregnancies and ongoing pregnancies.
Ethical approval
Ethical review board approval for the study was not relevant because of the nature of the study.
RESULTS
Demographics and availability
The responding clinics are large in terms of IVF+PGT cycle volumes in a Nordic context with the 
public funded clinics being largest. Figure 1 shows the annual number of oocyte retrievals and 
frozen/thawed embryo transfers.
Seven of the eight responding clinics offer PGT-M and PGT-SR while one exclusively offers PGT-A 
within a research protocol. Two clinics offer PGT with human leukocyte antigen (HLA) testing and 
one offers mitochondrial DNA (mtDNA) quantification. Three of the seven PGT-M/SR clinics also 
offer PGT-A as a stand-alone option, the others use aneuploidy data only as part of the analysis for 
PGT-SR. Figure 2 shows the cycle volumes for the main PGT techniques.
Organization
Table 1 shows highlights regarding the responding clinics from the text below. Six of the clinics are 
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two cases a genetic counsellor is employed by the IVF clinic, five collaborate to varying degrees with 
the local University Hospital department of Clinical Genetics (three have allocated a dedicated 
specialist in the Clinical Genetics department) and one in collaboration with a genetics service 
provider.
None of the IVF-clinics runs an in-house genetic analysis. Four collaborate with the Clinical Genetics 
or Genomic Medicine departments of their own hospital and one is affiliated with the local hospital. 
Two clinics cooperate with Cooper Genomics and one with Igenomix UK, Invicta or BioArray, and in 
specific cases elsewhere, which are international private service providers, specialized in clinical 
molecular genetics.
Seven of the eight clinics have at least one dedicated clinician for the PGT-program in the IVF clinic 
and one clinic has a dedicated embryologist for this purpose. One clinic has two dedicated 
embryologists performing embryo biopsies and the other five have at least three dedicated 
embryologists performing the biopsies. Training of embryologists in performing embryo biopsy was 
achieved at courses or workshops (N=6), at other IVF laboratories (N=1) and all laboratories 
performed in house training (N=8). Training in embryo biopsy was validated in all laboratories, by 
internal controls (N=7) and/or by external evaluation (N=4).
Availability
For clinics performing PGT-M/SR the waiting lists are less than one year, four report 1-3 months, one 
reports 4-6 months and two centers report a 6-12 months waiting list. This includes the genetics work 
up of patients. For clinics performing PGT-A, waiting lists are short, less than three months or no 
waiting list at all.
For PGT-M/SR, four clinics treat international patients: two clinics report 10-25% international 
patients, one reports 25-50% international patients and one clinic has only a few international patients 
per year. For PGT-A, two centers report 25-50% international patients.
In the two private clinics, patients pay an additional fee for PGT-A on top of the costs for IVF, either 
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Patient selection
Ovarian reserve and response
Five of the responding clinics have no lower limits regarding ovarian reserve although one has a 
criterion of previous blastocyst transfer for inclusion in an ongoing PGT-A study. The remaining 
three all have a cut off level for anti Müllerian hormone, two of them also have a cut off regarding 
antral follicle count and one requires additionally a certain number of oocytes after FSH stimulation 
for inclusion in the PGT program.
Karyotyping
All centers perform karyotyping before PGT but for varying indications. Four perform karyotyping 
for PGT-SR carrier only, two for PGT-SR for both partners and one for PGT-M. Three perform 
karyotyping for PGT-A.
Indications
The most common indications for PGT-M are Huntington’s disease (five clinics), Familial 
adenomatous polyposis (two clinics), Myotonic dystrophy (three clinics), Fragile X syndrome (three 
clinics), Familial breast-ovarian cancer (BRCA 1 and BRCA 2, two clinics), Cystic Fibrosis (two 
clinics) and Marfan syndrome (two clinics).
Six of the reporting clinics allow PGT-M for Huntington’s disease with exclusion testing (i.e. 
identifying alleles from a relative carrying the mutation for Huntington’s disease allowing exclusion 
of embryos with risk of carrying a mutation for Huntington’s disease without revealing the carrier 
status of the parent at risk); however the numbers are low for that specific activity. Three centres 
report 1-5 cycles per year, the other three did not report cycle numbers for this category.
The most common indications for PGT-A are advanced maternal age (two clinics), recurrent 
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Six centers use PGT-A during PGT-SR/M for embryo prioritzation for embryo transfer, one of them 
only when the aneuploidy information is generated by the analysis used for detecting the genetic 
disorder.
IVF Laboratory techniques
Six of the eight embryology laboratories have dedicated areas for tubing, five of eight have dedicated 
areas for embryo biopsy while the others use regular workstations for these procedures.
Protective gloves and gown are used during biopsy and tubing in seven of the embryology 
laboratories. In six laboratories a mask is used and in four of them as a minimum the biopsy pipette is 
changed between biopsies within the same patient. The holding pipette is not always changed between 
biopsies within the same patient. All of the eight laboratories change pipettes between tubing and six 
use negative control for each tubing.
DNA decontamination is applied for cleaning microscope and manipulators in five of the embryology 
laboratories and seven apply DNA decontamination for the tubing work-station.
Six laboratories perform intracytoplasmic sperm injection (ICSI) in all PGT cases whereas two 
perform ICSI only for PGT-M, otherwise IVF (unless the sperm sample motivates ICSI).
Biopsy technique
In one laboratory, zona breaching is exclusively performed at the cleavage stages to allow 
spontaneous hatching of the blastocyst before biopsy. The other laboratories perform zona breaching 
at the day of blastocyst biopsy. Three of the laboratories perform embryo biopsy both at the cleavage 
stage and the blastocyst stage depending on the case. In one laboratory this is operator dependent. 
Embryo biopsy is performed in all laboratories on days 5 and 6, additionally in one laboratory embryo 
biopsy is also performed on day 7. Details are shown in Table 2.
Two laboratories use exclusively laser cutting for biopsy dissection, the other six use either laser or 
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All laboratories use the Gardner’s grading system with the minimum blastocyst grade for biopsy 
being expansion grade 3 in six laboratories and grade 4 in the remaining two. Three have a minimum 
of inner cell mass grade C and four laboratories apply a minimum inner cell mass grade B for biopsy. 
Three have a minimum trophectoderm grade C for biopsy and four have a minimum trophectoderm 
grade B for biopsy. One laboratory makes an individual judgment depending on the case.
Three laboratories perform embryo biopsy at the cleavage stage for embryos with a minimum of six 
blastomeres required for biopsy and one specifies a maximum of 20% fragmentation.
Quality
Six of the IVF-laboratories apply systematic quality control, such as International Organization for 
Standardization (ISO), and five of the genetics laboratories as well. Two centers report no systematic 
quality control.
None of the laboratories have automated witnessing procedures. Five of the embryology laboratories 
apply manual witnessing of procedures by a colleague in the procedure and in the laboratory in 
general. Three of the laboratories have no witnessing procedures in place.
Genetic analysis and interpretation
The analysis platform used for analysis of chromosomal aberrations is Massive Parallel Sequencing 
(MPS) (also called Next Generation Sequencing (NGS)) as reported by six centers.
The platform used in PGT-M is MPS in one center, PCR based methods in four centers, single 
nucleotide polymorphism (SNP) array or karyomapping in five centers. Some centers use multiple 
techniques depending on the case.
The platform used for the genetic analysis in PGT-SR is MPS in six centers and fluorescence in situ 
hybridization (FISH) in two of which one is now launching an MPS platform.
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In all centers the PGT results are interpreted by specialists from the genetics lab performing the 
analysis and in one center it is the embryologist responsible for the PGT-program. Additionally, one 
clinic reports that the responsible clinician is included in interpreting the analysis and two report that 
the laboratory director is included in the interpretation of results. One clinic includes the genetic 
counsellor in cases where interpretation is not clear.
The maximum degree of mosaicism allowed for considering a blastocyst for transfer is 20% in one 
center, 30% in one center, 40% in three centers and 50% in one center. One center makes evaluations 
on a case by case basis focusing more on which chromosomes are involved rather than the level of 
mosaicism. One clinic does not transfer mosaic blastocysts at all. If mosaic blastocysts are transferred, 
patients receive separate genetic counselling in all clinics.
Three clinics recommend prenatal testing after PGT-A, six clinics after PGT-M/SR and two do not 
recommend prenatal testing after PGT. One of the latter clinics makes an exception if a mosaic 
blastocyst is transferred or if the genetic test has a lower accuracy compared to the applicable 
standard, e.g. 95% instead of 99%.
In one laboratory aneuploid embryos are automatically discarded after results are obtained whereas 
the other laboratories will store for research or future evaluation. Seven centers will not transfer 
aneuploid embryos by patient demand, one did not respond.
Figure 3 shows the PGT-A results in terms of the proportion of euploid embryos from the four clinics 
reporting stand-alone PGT-A, i.e. not including the combination of PGT-SR/A or PGT-M/A.
Clinical and laboratory results
The number of oocytes retrieved in PGT cycles ranges from 8-14 with no obvious correlations 
between clinics applying strict anti Müllerian hormone or antral follicle count cut off values and those 
which do not (data not shown). The proportion of cycles with no embryos to biopsy ranged from 0-
30% and the average number of embryos biopsied per cycle was between two and five for the various 
clinics. The proportion of cycles with no embryos to transfer ranged from 22-60%, lowest in PGT-M 
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Genetic analysis
The proportion of failed/inconclusive results in the genetic analysis ranged from 0-12%, highest in 
PGT-M. Summary results of the chromosomal analysis in PGT-A were provided by four clinics. The 
proportion of euploid blastocysts ranged from 25% to 45%, aneuploid from 42% to 70%, mosaic from 
0% to 21% (Figure 3).
Clinical pregnancy rate
Clinical pregnancy rates for PGT-M/SR/A are presented in Table 2. Results range from 31% to 60% 
for PGT-M and from 27% to 75% for PGT-SR. Three clinics performed some Day 3 biopsy and fresh 
Day 4-5 transfers which are included in these results as numbers are low. Table 2 shows that the 
actual numbers of transfers in each group are in many cases low which means that the rates must be 
interpreted with caution. Data on clinical and ongoing pregnancy rates after PGT-A with single 
euploid blastocyst frozen-thawed embryo transfer were provided by three clinics with clinical 
pregnancy rates varying from 30% to 67%. The reported miscarriage rate was low with only one 
pregnancy loss reported for 2018 for PGT-A.
DISCUSSION
The present study presents unique data on the current status of PGT practices in the Nordic countries, 
representing the majority of PGT cycles performed in these countries. We estimate that the present 
data collection represents >95% of the PGT-M/SR cycles and at least 75% of the PGT-A cycles 
currently performed in the Nordic countries. In general, the results presented here in terms of 
pregnancy rates, rates of utilizable embryos and general quality aspects are well comparable or even 
superior to international data. The most recent ESHRE data from 2017 reported at the ESHRE 
consortium meeting in 2019 showed a clinical pregnancy rate of 20-25% per embryo transfer for 
PGT-M and PGT-SR (M De Rycke, personal communication). All of the clinics in the Nordic data 
presents results at equal or higher levels. It should be noted that embryo biopsy at the blastocyst stage 
is more prevalent in this dataset although varying between clinics, as compared to the most recent as 
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PGT-A are more varied, but in general the Nordic results compare well with the most recent ESHRE 
consortium data, see Table 2, which shows clinical pregnancy rates per transfer of around 40% per 
transfer in the majority of clinics for all treatment modalities and across nationalities. There is a 
striking difference between results from the three clinics reporting PGT-A in terms of proportions of 
mosaic and aneuploid embryos as well as clinical and ongoing pregnancies. This may be partly due to 
relatively low numbers of cycles, differences in patient populations including age (which were not 
accessible in this survey), but issues such as embryo culture, biopsy techniques, the diagnostic 
platforms and the interpretation of results (for example regarding the definition of mosaicism) may 
also be involved. However, many recent publications show very high clinical pregnancy rates per 
transfer when applying PGT-A, higher than the ESHRE average, although the difference might be 
explained by the difference in biopsy stage between newer studies and the ESHRE data.24
The clinical indications for PGT-M also compare well with the ESHRE consortium data in general 
with four out of five indications being identical to the top ones from the ESHRE dataset.11
Another interesting indicator of quality is the proportion of utilizable embryos, mostly regarding 
PGT-A but also for other indications. This has been discussed as an important quality indicator for 
both laboratory and clinical procedures.25 The proportion of euploid embryos seems lower in the 
reporting Nordic clinics (Figure 3) in comparison with the ESHRE consortium data. Further, the rate 
of inconclusive results varied within the study. This can be related to the varied patient populations 
with parameters such as patient age possibly playing a role, but may also reflect technical aspects 
since in the published ESHRE data some clinics are still using older analysis methods and not MPS. 
Variance in the rate of inconclusive diagnoses between centers might be expected given differences in 
platforms used and interpreter skills, but the small sample sizes in the given dataset might also explain 
much of the variance.
Varying degrees of mosaicism in embryos is an issue which has become apparent in recent years. The 
International Preimplantation Genetic Diagnosis Society (PGDIS) has recently issued a statement 
regarding how to handle embryo mosaicism with recommendations on acceptable degrees of 
mosaicism, informed patient consent, prenatal testing and other issues.26 The Nordic clinics allow 
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these cases. The degree of mosaicism accepted has been changing over time and will continue to do 
so, as knowledge and safety issues influence opinions. Prenatal testing is not uniformly recommended 
by Nordic clinics after PGT. Nevertheless, misdiagnoses have been reported after PGT, and prenatal 
testing is recommended after PGT by the ESHRE PGTM working group.
Dedicated laboratory areas and strict quality measures are important to minimize contamination and 
maximize reliability of the analyses in PGT as specified in the most recent ESHRE recommendations. 
Most, but not all of the Nordic IVF laboratories are compliant in this respect. As noninvasive PGT by 
analyzing used culture media and/or blastocoel fluid is being introduced internationally, the 
importance of high laboratory standard becomes even more important and avoiding contamination of 
the samples by foreign DNA even more critical.27, 28 Two clinics did not during the time period of the 
study perform biopsy in a special area dedicated for PGT, which is hardly in accordance with 
international guideline and represents a risk of contamination. One of the additional challenges for 
noninvasive PGT is avoiding potential maternal contamination in the culture medium which may be 
difficult to achieve despite all efforts to ensure a contamination free laboratory environment.29
The interest in PGT is increasing internationally. It is expected that non-invasive testing will increase 
the implementation of this technique, making the embryological work easier and potentially 
increasing accuracy of the methods,27 although more research is warranted prior to clinical 
implementation. Additionally, the introduction of preconception carrier screening, where couples are 
proactively screened for recessive disorders and other conditions prior to even attempting pregnancy 
is becoming a realistic option.30 This will likely increase the use of PGT in coming years and will 
place new and different demands on the clinics and genetic laboratories although many issues 
regarding this concept need to be addressed before large scale implementation.31 Monitoring of the 
activities and continuous quality improvement are the key to offer patients high standards of care.
CONCLUSION
The present survey shows that PGT is organised in relatively few clinics in the Nordic countries. All 









This article is protected by copyright. All rights reserved
for analysis of the biopsies. Laboratory procedures are largely in accordance with international 
guidelines. The platform for analysis of chromosomal aberrations is MPS as reported by six centers. 
The degree of mosaicism allowed for a transferable embryo varied from 0 to 50%. PCR is still used 
for PGT-M in half of the centers. The outcome after PGT in terms of clinical pregnancy per transfer is 
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Figures and Table
Figure 1. Size of the reporting clinics in terms of the total number of oocyte retrievals (OPU) and 
frozen/thawed embryo transfer (FET) cycles per year, including preimplantation genetic testing. Y-
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Figure 2. Cycle volume in terms of oocyte retrievals for the various preimplantation genetic testing 
(PGT) techniques. Y-axis indicates the number of oocyte retrievals. PGT-A, PGT for aneuploidies; 
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Figure 3. Chromosomal analysis and proportion of embryo euploidy from the four clinics reporting 
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Table 1. Details on methods and status of reporting clinics. 
Nationality
Organization
Counselling and genetic 
analysis
Waiting list for 
PGT-M/SR
Day of biopsy, minimum 









Clinic 1 Finland, Private Own genetic counsellor. 
Private vendor for analysis
<3 months Biopsy days 5-7, minimum 
grade 3. ZP breached at the day 
of blastocyst biopsy





Clinic 2 Sweden, Public University clinic based 
counselling. University 
genetics laboratory
<3 months Biopsy days 3, 5, 6. Grade 4BB 
min. or 6 blastomeres day3. ZP 
breached at the day of blastocyst 
biopsy






Clinic 3 Sweden, Public University clinic based 
counselling. University 
genetics laboratory
<12 months Biopsy days 3, 5, 6. Grade 3BB 
min. or 6 blastomeres day3. ZP 
breached at the day of blastocyst 
biopsy







Clinic 4 Denmark, 
Private
Own genetic counsellor. 
Private vendor for analysis
<3 months Biopsy days 5, 6. Grade 4CC. 







Clinic 5 Denmark, 
Public
University clinic based 
counselling. University 
genetics laboratory
<3 months Biopsy days 5, 6. Grade 3BB 








Clinic 6 Finland, Public University clinic based 
counselling. Private vendor 
for analysis
<6 months Biopsy days 5, 6. Grade 3BC 
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Clinic 7 Denmark, 
Public
University clinic based 
counselling. University 
genetics laboratory
n.a. Biopsy days 5, 6. Grade 3CB 
min. ZP breach at the day of 
blastocyst biopsy
UV light Genetics dept. MPS
Clinic 8 Denmark, 
Public
University clinic based 
counselling. University 
genetics laboratory
<12 months Biopsy days 3, 5, 6. Grade 3CC 
min. or 6 blastomeres day3. ZP 
breached at the day of blastocyst 
biopsy






PGT, preimplantation genetic testing;  M; for monogenic disorders;  SR, for structural rearrangements; ZP, zona pellucida; ISO; International Organization for 
Standardization; EtOH, ethanol; UV, ultraviolet; IVF, in vitro fertilization; MPS, Massive Parallel Sequencing; SNP, single nucleotide polymorphism; polymerase 
chain reaction; FISH, fluorescence in situ hybridization; Gardner blastocyst grading system. Expansion: 1 to 6; Inner Cell Mass (ICM): A, B or C; Trophectoderm 
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Table 2. Treatments offered and the number of frozen/thawed embryo replacements (FET), ongoing pregnancies (OP) and pregnancy rates 
































Clinic 3 PGT-M/SR * * * 163 57 35%
(28-43)
0
















Clinic 7 PGT-A 0 0 18 12 67%
(43-84)





In PGT-SR chromosomal status is taken into account when selecting embryos for transfer even if the clinic otherwise does not offer PGT-A.
*Clinic 3 presents combined data for PGT-M and PGT-SR. In clinic 8, PGT-SR was performed by Day3 biopsy and fluorescence in situ hybridization (FISH) without 










PGT-M, preimplantation genetic testing for monogenic disorders; PGT-SR, preimplantation genetic testing for structural rearrangements, PGT-A, preimplantation 
genetic testing for aneuploidies.
